PE20071063A1 - Formulaciones de proteinas estables - Google Patents
Formulaciones de proteinas establesInfo
- Publication number
- PE20071063A1 PE20071063A1 PE2006001649A PE2006001649A PE20071063A1 PE 20071063 A1 PE20071063 A1 PE 20071063A1 PE 2006001649 A PE2006001649 A PE 2006001649A PE 2006001649 A PE2006001649 A PE 2006001649A PE 20071063 A1 PE20071063 A1 PE 20071063A1
- Authority
- PE
- Peru
- Prior art keywords
- sugar
- protein formulations
- stable protein
- formulation
- ctla4ig
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
REFERIDA A UNA FORMULACION ESTABLE QUE COMPRENDE AL MENOS 100 MG/ML DE MOLECULAS DE CTLA4Ig, UN AZUCAR TAL COMO SUCROSA, MALTOSA, LACTOSA, MANITOL, ENTRE OTRAS, Y UN PORTADOR ACUOSO FARMACEUTICAMENTE ACEPTABLE. LA MOLECULA CTLA4Ig TIENE LA SECUENCIA DE AMINOACIDOS MOSTRADA EN LA SEQ ID NO:2 COMENZANDO CON METIONINA EN LA POSICION 27 O ALANINA EN LA POSICION 26 Y TERMINANDO EN LA LISINA EN LA POSICION 383 O GLICINA EN LA POSICION 382. DICHA FORMULACION TIENE UNA PROPORCION DE PROTEINA Y AZUCAR DE 1:1.3 Y TIENE UN pH ENTRE 6 Y 8. LA FORMULACION PUEDE SER LIOFILIZADA O LIQUIDA Y SE PUEDE ADMINISTRAR VIA INTRAVENOSA O SUBCUTANEA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75215005P | 2005-12-20 | 2005-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071063A1 true PE20071063A1 (es) | 2007-10-24 |
Family
ID=38057529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001649A PE20071063A1 (es) | 2005-12-20 | 2006-12-19 | Formulaciones de proteinas estables |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8476239B2 (es) |
| EP (1) | EP1962886B2 (es) |
| JP (2) | JP5247467B2 (es) |
| KR (1) | KR101378194B1 (es) |
| CN (3) | CN101584858A (es) |
| AR (2) | AR058567A1 (es) |
| AU (1) | AU2006330593B2 (es) |
| BR (1) | BRPI0622256A2 (es) |
| CA (1) | CA2634547C (es) |
| CL (1) | CL2010000816A1 (es) |
| DK (1) | DK1962886T4 (es) |
| EA (1) | EA014232B1 (es) |
| ES (1) | ES2436616T5 (es) |
| HR (1) | HRP20131196T4 (es) |
| IL (1) | IL192104A (es) |
| NO (1) | NO347247B1 (es) |
| NZ (1) | NZ569108A (es) |
| PE (1) | PE20071063A1 (es) |
| PL (1) | PL1962886T6 (es) |
| PT (1) | PT1962886E (es) |
| RS (1) | RS53127B2 (es) |
| SG (1) | SG153832A1 (es) |
| TW (3) | TW200738261A (es) |
| WO (1) | WO2007076354A2 (es) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2439641T3 (es) | 2005-12-20 | 2014-01-24 | Bristol-Myers Squibb Company | Composiciones y procedimientos de producción de una composición |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| TW200738261A (en) * | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| CN102170919A (zh) | 2008-10-06 | 2011-08-31 | 三维肽胶株式会社 | 组织闭塞剂 |
| EP2445616B1 (en) * | 2009-06-23 | 2018-05-02 | GE Healthcare Bio-Sciences AB | Simulator device |
| GB201009676D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
| JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
| US20140147418A1 (en) * | 2011-04-15 | 2014-05-29 | The Us Of America, As Represented By The Secretary Department Of Health And Human Services | Aav mediated ctla-4 gene transfer to treat sjogren's syndrome |
| EP2709653B1 (en) | 2011-04-20 | 2017-11-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
| TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| PT2763979T (pt) | 2011-10-07 | 2019-04-12 | Takeda Pharmaceuticals Co | Compostos de 1-arilcarbonil-4-oxi-piperidina úteis para o tratamento de doenças neurodegenerativas |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| EA026410B1 (ru) | 2011-10-18 | 2017-04-28 | Кохерус Байосайенсис, Инк. | Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| CN104520316B (zh) | 2012-06-29 | 2021-07-06 | 百时美施贵宝公司 | 减少糖蛋白聚集的方法 |
| CN104902974B (zh) * | 2012-07-06 | 2017-07-28 | 三维矩阵有限公司 | 肽溶液的灌装加工法 |
| BR112015000203A2 (pt) | 2012-07-09 | 2017-06-27 | Coherus Biosciences Inc | formulações de etanercept que exibem redução marcada em partículas sub-visíveis |
| AU2013308470B2 (en) | 2012-08-31 | 2017-04-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | AAV mediated aquaporin gene transfer to treat Sjogren's syndrome |
| PE20150964A1 (es) | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| WO2014043103A1 (en) | 2012-09-11 | 2014-03-20 | Coherus Biosciences, Inc. | Correctly folded etanercept in high purity and excellent yield |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| EP2996772B1 (en) | 2013-05-13 | 2018-12-19 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| CN103385852B (zh) * | 2013-08-06 | 2015-03-11 | 南京正大天晴制药有限公司 | 一种盐酸法舒地尔注射液及其制备方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| BR112016020584A2 (pt) | 2014-03-10 | 2017-10-03 | 3 D Matrix Ltd | Composições de peptídeo auto-organizável |
| US10369237B2 (en) | 2014-03-10 | 2019-08-06 | 3-D Matrix, Ltd. | Sterilization and filtration of peptide compositions |
| EP3119809A1 (en) | 2014-03-19 | 2017-01-25 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40l |
| ES2910443T3 (es) * | 2014-04-16 | 2022-05-12 | Biocon Ltd | Formulaciones de proteínas estables que comprenden un exceso molar de sorbitol |
| EA201692126A1 (ru) | 2014-04-25 | 2017-03-31 | Бристол-Маерс Сквибб Компани | Способ достижения безлекарственной ремиссии у субъектов с ранним ревматоидным артритом (ra, ра) |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| ES2818109T3 (es) | 2014-06-23 | 2021-04-09 | Novartis Ag | Modificaciones de proteínas específicas para un sitio |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| CN106999510B (zh) | 2014-10-01 | 2021-04-30 | 伊格尔生物制品有限公司 | 含有粘度降低剂的多糖和核酸制剂 |
| EP3207936B1 (en) | 2014-11-18 | 2021-04-21 | Shionogi & Co., Ltd. | Stable peptide composition |
| CR20170338A (es) | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de ácidos grasos y apelina sintética con mayor vida media |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| DK3347031T3 (da) * | 2015-09-11 | 2021-04-26 | Nutrition & Biosciences Usa 1 Llc | Sammensætning, der omfatter et protein og en polyalkoxyfedtforbindelse |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| MY195681A (en) * | 2015-12-07 | 2023-02-03 | Merck Patent Gmbh | Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab |
| WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
| EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| RU2770209C2 (ru) | 2017-05-24 | 2022-04-14 | ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ | Терапевтические антитела против лиганда cd40 |
| KR20200103733A (ko) | 2017-12-22 | 2020-09-02 | 노파르티스 아게 | Fgf21 변이체로 대사 장애를 치료하는 방법 |
| CN108014338A (zh) * | 2018-01-22 | 2018-05-11 | 安徽未名生物医药有限公司 | 一种注射用巴利昔单抗冻干粉针及其制备方法 |
| SG11202011354VA (en) * | 2018-05-25 | 2020-12-30 | Dr Reddys Laboratories Ltd | Ctla4-ig fusion protein formulation |
| AU2019274826A1 (en) * | 2018-05-25 | 2021-01-07 | Dr. Reddy's Laboratories Ltd. | Stable fusion protein formulation |
| WO2020003139A2 (en) * | 2018-06-26 | 2020-01-02 | Lupin Limited | Stable lyophilized dosage form of protein |
| CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| CN113396158A (zh) | 2018-11-26 | 2021-09-14 | 诺华股份有限公司 | Lpl-gpihbp1融合多肽 |
| IL284868B2 (en) | 2019-01-15 | 2025-09-01 | Inst Nat Sante Rech Med | Mutant interleukin-34 (IL-34) polypeptides and their use for medical therapy |
| US20220098252A1 (en) | 2019-01-25 | 2022-03-31 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
| GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
| US20230071973A1 (en) * | 2019-12-20 | 2023-03-09 | Anthos Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
| GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
| EP4284841A1 (en) * | 2021-02-01 | 2023-12-06 | Dr. Reddy's Laboratories Limited | Compositions comprising fusion protein and analytical attributes thereof |
| CA3212856A1 (en) | 2021-03-23 | 2022-09-29 | John Maher | Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof |
| CN113925963B (zh) * | 2021-10-15 | 2023-08-11 | 江苏太平洋美诺克生物药业股份有限公司 | 一种稳定的包含抗cd147单克隆抗体的药物制剂 |
| GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
| IL319340A (en) * | 2022-09-29 | 2025-05-01 | Pfizer | Immunogenic preparations containing RSV F protein truncation |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
| WO2025196207A1 (en) | 2024-03-20 | 2025-09-25 | King's College London | Compositions and methods for use in depleting senescent cells and treating aging |
| WO2026021575A1 (zh) * | 2024-07-26 | 2026-01-29 | 鸿运华宁（杭州）生物医药有限公司 | 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019020A1 (en) * | 1993-02-23 | 1994-09-01 | Genentech, Inc. | Excipient stabilization of polypeptides treated with organic solvents |
| DE4405426A1 (de) * | 1994-02-21 | 1995-08-24 | Boehringer Mannheim Gmbh | Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate |
| CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| WO2003005465A1 (en) | 2001-04-25 | 2003-01-16 | Quallion, Llc | Rechargeable lithium battery for tolerating discharge to zero volts |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| TWI322153B (en) | 2000-07-03 | 2010-03-21 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| AU2002243905B2 (en) * | 2001-01-26 | 2007-11-08 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| WO2003042344A2 (en) * | 2001-11-13 | 2003-05-22 | Genentech, Inc. | Apo2 ligand/trail formulations |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| PL213311B1 (pl) | 2002-02-14 | 2013-02-28 | Chugai Pharmaceutical Co Ltd | Preparat roztworu zawierajacego przeciwcialo |
| AU2003303394B2 (en) | 2002-12-23 | 2009-02-19 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
| CA2511520A1 (en) | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| PL1610820T5 (pl) * | 2003-04-04 | 2014-01-31 | Genentech Inc | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
| BRPI0413326A (pt) * | 2003-08-04 | 2006-10-10 | Bristol Myers Squibb Co | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US7790679B2 (en) * | 2005-08-05 | 2010-09-07 | Amgen Inc. | Pharmaceutical formulations |
| TW200738261A (en) * | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
-
2006
- 2006-12-19 TW TW095147647A patent/TW200738261A/zh unknown
- 2006-12-19 EA EA200801570A patent/EA014232B1/ru active Protection Beyond IP Right Term
- 2006-12-19 ES ES06846683T patent/ES2436616T5/es active Active
- 2006-12-19 NO NO20082628A patent/NO347247B1/no unknown
- 2006-12-19 BR BRPI0622256-0A patent/BRPI0622256A2/pt not_active Application Discontinuation
- 2006-12-19 HR HRP20131196TT patent/HRP20131196T4/hr unknown
- 2006-12-19 DK DK06846683.8T patent/DK1962886T4/da active
- 2006-12-19 US US12/086,876 patent/US8476239B2/en active Active
- 2006-12-19 TW TW098139141A patent/TW201008595A/zh unknown
- 2006-12-19 JP JP2008547721A patent/JP5247467B2/ja active Active
- 2006-12-19 CN CNA2009101398246A patent/CN101584858A/zh active Pending
- 2006-12-19 PT PT68466838T patent/PT1962886E/pt unknown
- 2006-12-19 KR KR1020087017544A patent/KR101378194B1/ko active Active
- 2006-12-19 CA CA2634547A patent/CA2634547C/en active Active
- 2006-12-19 EP EP06846683.8A patent/EP1962886B2/en active Active
- 2006-12-19 AU AU2006330593A patent/AU2006330593B2/en active Active
- 2006-12-19 WO PCT/US2006/062297 patent/WO2007076354A2/en not_active Ceased
- 2006-12-19 NZ NZ569108A patent/NZ569108A/en unknown
- 2006-12-19 PE PE2006001649A patent/PE20071063A1/es active IP Right Grant
- 2006-12-19 SG SG200904148-4A patent/SG153832A1/en unknown
- 2006-12-19 TW TW098139142A patent/TWI393575B/zh active
- 2006-12-19 CN CN200910139825A patent/CN101822820A/zh active Pending
- 2006-12-19 CN CN2006800530514A patent/CN101378773B/zh active Active
- 2006-12-19 AR ARP060105626A patent/AR058567A1/es not_active Application Discontinuation
- 2006-12-19 PL PL06846683.8T patent/PL1962886T6/pl unknown
- 2006-12-20 RS RS20130553A patent/RS53127B2/sr unknown
-
2008
- 2008-06-12 IL IL192104A patent/IL192104A/en active IP Right Grant
-
2010
- 2010-07-30 CL CL2010000816A patent/CL2010000816A1/es unknown
-
2011
- 2011-06-27 JP JP2011141983A patent/JP5538309B2/ja active Active
-
2014
- 2014-09-04 AR ARP140103315A patent/AR097561A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071063A1 (es) | Formulaciones de proteinas estables | |
| US20250034545A1 (en) | Modifications of peptide compositions to increase stability and delivery efficiency | |
| WO2005021579A3 (en) | Epo mimetic peptides and fusion proteins | |
| NO20015584D0 (no) | Lantidsvarende insulintrofiske peptider | |
| AR117403A2 (es) | Formulaciones de anticuerpos | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| EP1626055A3 (en) | Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| CA2187083A1 (fr) | Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation | |
| NZ592510A (en) | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same | |
| SI1687019T1 (en) | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices | |
| JP2008535819A5 (es) | ||
| NZ593311A (en) | Albumin binding peptide-mediated disease targeting | |
| CA2485217A1 (en) | Insulin-associated peptides with effects on cerebral health | |
| RU2010111139A (ru) | Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства | |
| TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. | |
| CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
| WO2004112838A3 (en) | Codrugs of diclofenac | |
| WO2002058589A3 (en) | Agents and methods for promoting bone growth | |
| CA2373252A1 (en) | Long lasting anti-angiogenic peptides | |
| KR890003409A (ko) | 점막 투여시 흡수 촉진제로서의 시클릭 펩티드 | |
| TW200505943A (en) | Polypeptide | |
| JP2005506276A5 (es) | ||
| AU3739500A (en) | Protease resistant flint analogs | |
| EP1586581A3 (en) | Non-Mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |